NeuroSense Therapeutics Ltd. (NRSN) Form 6-K — Nov 2, 2026
NeuroSense Therapeutics announced it will strengthen its New Drug Submission to Health Canada for PrimeC, its lead ALS therapy, by adding new neurofilament light chain (NfL) biomarker data to the Phase 2b PARADIGM results published in JAMA Neurology. This would be PrimeC's first marketing application in any jurisdiction. The filing target has shifted from December 2026 to March 2027 to accommodate the new data; Health Canada confirmed it has no concerns with the revised timing and a standard ~300-day review would follow acceptance. PrimeC-treated participants showed greater NfL reduction versus placebo, with a more pronounced effect in participants with higher baseline functionality.
Key figures
- Filing timeline
- March 2027 (updated from December 2026)
- Canadian als patients
- approximately 4,000
- Us annual als diagnoses
- more than 5,000
- Us annual disease burden usd
- $1 billion
- Als patient growth 2040 us eu
- 24%
- Annual new canadian diagnoses
- approximately 1,000
- Health canada review target days
- 300
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.